Robert W. Baird Lowers LivaNova (NASDAQ:LIVN) Price Target to $76.00

LivaNova (NASDAQ:LIVN) had its price objective cut by equities research analysts at Robert W. Baird from $78.00 to $76.00 in a report released on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 5.76% from the stock’s previous close.

A number of other equities analysts have also weighed in on the company. Stifel Nicolaus set a $80.00 price objective on LivaNova in a research note on Wednesday, February 25th. Needham & Company LLC raised their target price on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Piper Sandler reiterated an “overweight” rating and set a $85.00 price target on shares of LivaNova in a research report on Thursday, February 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a report on Friday, March 27th. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $66.00 price objective on shares of LivaNova in a research report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $77.22.

LivaNova Stock Up 1.3%

NASDAQ:LIVN opened at $71.86 on Thursday. The firm has a market capitalization of $3.95 billion, a P/E ratio of 36.85 and a beta of 0.82. LivaNova has a 1-year low of $41.01 and a 1-year high of $72.51. The company’s fifty day moving average price is $64.01 and its 200-day moving average price is $62.15. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.16.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. During the same period in the previous year, the firm posted $0.88 earnings per share. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, equities research analysts anticipate that LivaNova will post 3.66 EPS for the current year.

Institutional Trading of LivaNova

Several institutional investors have recently bought and sold shares of LIVN. Millennium Management LLC increased its position in shares of LivaNova by 17.3% in the fourth quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock valued at $214,376,000 after buying an additional 514,268 shares in the last quarter. Artisan Partners Limited Partnership lifted its position in shares of LivaNova by 94.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after buying an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP grew its stake in LivaNova by 83.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after acquiring an additional 1,067,349 shares during the period. Vanguard Group Inc. grew its stake in LivaNova by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock valued at $143,491,000 after acquiring an additional 34,812 shares during the period. Finally, AQR Capital Management LLC increased its holdings in LivaNova by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock worth $132,606,000 after acquiring an additional 496,165 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.